Medication-use related endocrine disruption reported to the local pharmacovigilance program in Bogota, during 2012- 2016

Authors

DOI:

https://doi.org/10.18270/rsb.v9i1.2641

Keywords:

Endocrine system, Adverse reactions to medicinal products, Cinacalcet, Prednisolone, Adalimumab, Risperidone, Amiodarone,, Goiter, Hypothyroidism, Hyperprolactinemia

Abstract

Objective. Becoming familiar with medication-use related endocrine disruption reported to the local pharmacovigilance program in Bogotá during 2012-2016. Tools and methods. Analyzed reports are dated between January 1st, 2012 and December 31st, 2016 and were gathered from the Pharmacovigilance Program in Bogotá. The analysis of the said reports was conducted through causality algorithms and event type.


Results. Out of 87 analyzed reports, two were not included in the study due to lack of information for its classification in one case and, medication-related problems in another case. 36 reports (42.9 %) were found to have adverse reaction to type A medications, while 26 reports (34.1%) were found to have medication related problem type therapeutic failure. The main medication related problems were associated to the use of Cinacalcet with increased levels of parathormone in 27 out of 87 analyzed reports in this study. Other medication related problems found were: Cushing Syndrome, associated with the use of prednisolone in 12 reports; Goiter associated to the use of adalimumab in 12 reports; Hyperprolactinemia associated to the use of Risperidone in 10 reports and, Hypothyroidism associated to the use of Amiodarone in 3 reports.


Conclusions: Carrying out such studies allows for the understanding of the main medication-use problems that are shown during common use of medications, as well as their safety profile.

Downloads

Download data is not yet available.

References

Roca A. Capítulo 1 Hormona, receptores y Control endocrino. En: Fisiología endocrina. Bogotá (Colombia): Academia Nacional Medicina; 2005. p 6-10 [Disponible en: http://www.revistamedicina.net/anmdecolombia.net/images/documentos/FisiologiaEndocrina1.pdf] [citado el 6 de Mayo del 2019].

Escrivá J, Carbajal J, Mendaza M. Endocrinología. En: Gamundi M.Farmacia hospitalaria II tomo. Madrid (España): Sociedad española de farmacia hospitalaria; 2002. p 877-918 [https://www.sefh.es/sefhpublicaciones/fichalibrolibre.php?id=24][citado el 6 de Mayo del 2019].

Serra H, Roganovich J, Rizzo L. Glucocorticoides: paradigma de medicina traslacional de lo molecular al uso clínico. Medicina (B Aires). 2012; 72:158-70.

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017; 58:70-6.

González C, Gutiérrez J, Pedraza R, Figueras A. Algorithm for the evaluation of therapeutic failure reports--proposal and pilot analysis. Pharmacoepidemiol Drug Saf. 2013;22: 199-206.

Orellana JM, Esteban RJ, Castilla YA, Fernández-Castillo R, Nozal-Fernández G, Esteban MA, Bravo J. Use of cinacalcet for the management of hyperparathyroidism in patients with different degrees of renal failure. Nefrología. 2016; 36:121-5.

Kunwar AR, Megn JL. Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. Ann Pharmacother. 2003;37:206-8.

Sánchez J, Gutiérrez, J. Fallo terapéutico de levotiroxina en el manejo de hipotiroidismo en una institución de salud de Bogotá, D.C. Un estudio analítico de prevalencia. Revista Colombiana de Ciencias Químico-Farmacéuticas. 2015; 44:16-33.

Señaris J. Trastornos de las paratiroides. Medicine. 2008;10: 1057-62.Bernal M de. Prolactina. Diabetes y metabolismo. Revista Colombiana de Endocrinología. 2018;12:38-45.

Restrepo JG, Sierra GL, Maya GC. Síndrome de Cushing. Medicina y Laboratorio. 2009;15:411-30.

Galofré J. Manejo de los corticoides en la práctica clínica. Revista Médica de la Universidad de Navarra. 2009; 53:9-18.

Published

2019-08-06

How to Cite

Ordoñez, N. J., & Sánchez Castillo, J. (2019). Medication-use related endocrine disruption reported to the local pharmacovigilance program in Bogota, during 2012- 2016. Revista Salud Bosque, 9(1), 27–32. https://doi.org/10.18270/rsb.v9i1.2641

Issue

Section

Scientific articles: